To the Editor: Two months of treatment with
rifampin and pyrazinamide is effective in preventing tuberculosis (TB) in
tuberculin-positive, human immunodeficiency virus (HIV)-seropositive individuals.1,2 Recent reports, however, have
raised concerns about the safety of rifampin and pyrazinamide for latent TB
infection in HIV-seronegative individuals, although toxicity incidence is
not known.3 The reported adverse events
have occurred with use of a daily regimen. We studied the outcomes of a twice-weekly
regimen of these medications to treat latent TB in 600 prison inmates in Maryland.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 24
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.